Isavuconazole: A comprehensive review of spectrum of activity of a new triazole

George R. Thompson, Nathan P. Wiederhold

Research output: Contribution to journalReview articlepeer-review

112 Scopus citations


Isavuconazole is a new triazole currently undergoing phase III clinical trials. This compound has shown in vitro activity against a large number of clinically important yeasts and moulds including Aspergillus spp., Fusarium spp., Scedosporium spp., Candida spp., the Zygomycetes and Cryptococcus spp. Similar to voriconazole, reduced in vitro activity is seen against Histoplasma capsulatum. In vivo efficacy has been demonstrated in murine models of invasive aspergillosis and candidiasis. Additionally, there are several potential pharmacokinetic and drug-drug interaction advantages of this compound over existing antifungal agents. This review summarizes existing data that has been either published or presented at international symposia.

Original languageEnglish (US)
Pages (from-to)291-313
Number of pages23
Issue number5
StatePublished - Nov 1 2010


  • Antifungal
  • Fungicidal
  • Fungistatic
  • In vitro activity
  • In vivo studies
  • Isavuconazole

ASJC Scopus subject areas

  • Microbiology
  • Applied Microbiology and Biotechnology
  • Agronomy and Crop Science
  • veterinary (miscalleneous)


Dive into the research topics of 'Isavuconazole: A comprehensive review of spectrum of activity of a new triazole'. Together they form a unique fingerprint.

Cite this